<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PLASMA-LYTE 56- sodium chloride, potassium acetate and magnesium acetate tetrahydrate injection </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>PLASMA-LYTE 56 Injection (Multiple
        Electrolytes Injection, Type 1, USP)<br>in VIAFLEX Plastic Container</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-ffb8bd22-1556-4d5d-a394-222093aa7e10"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="INV-05154d79-516c-4794-b86c-3fa60f20f610"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) is a sterile,
                            nonpyrogenic, hypotonic solution in a single dose container for
                            intravenous administration. Each 100 mL contains 234 mg of Sodium
                            Chloride, USP (NaCl); 128 mg of Potassium Acetate, USP
                                (C<span class="Sub">2</span>H<span class="Sub">3</span>KO<span class="Sub">2</span>); and 32 mg of Magnesium
                            Acetate Tetrahydrate
                                (Mg(C<span class="Sub">2</span>H<span class="Sub">3</span>O<span class="Sub">2</span>)<span class="Sub">2</span>•4H<span class="Sub">2</span>O).
                            It contains no antimicrobial agents. The pH is adjusted with
                            hydrochloric acid. The pH is 5.5 (4.0 to 8.0).</p>
<p><a name="INV-e4c28af2-2600-4bf7-a678-a5b4283da43c"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) administered
                            intravenously has value as a source of water and electrolytes. One liter
                            has an ionic concentration of 40 mEq sodium, 13 mEq potassium, 3 mEq
                            magnesium, 40 mEq chloride, and 16 mEq acetate. The osmolarity is 111
                            mOsmol/L (calc). Normal physiologic osmolarity range is approximately
                            280 to 310 mOsmol/L. Administration of substantially hypertonic
                            solutions may cause vein damage.</p>
<p><a name="INV-cf760b24-70ce-4995-ac0c-99b20e118d25"></a>The VIAFLEX plastic   container is fabricated from a specially formulated polyvinyl chloride
                            (PL 146 Plastic). The amount of water that can permeate from inside the
                            container into the overwrap is insufficient to affect the solution
                            significantly. Solutions in contact with the plastic container can leach
                            out certain of its chemical components in very small amounts within the
                            expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
                            per million. However, the safety of the plastic has been confirmed in
                            tests in animals according to USP biological tests for plastic
                            containers as well as by tissue culture toxicity studies.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-245d81a2-f6f6-4dfd-bec2-b43b74f60393"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="INV-19cf65b3-a45d-4bca-b275-0aefb21682a9"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) has value as a
                            source of water and electrolytes. It is capable of inducing <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>
                            depending on the clinical condition of the patient.</p>
<p><a name="INV-44ac1e0e-a23e-40a4-a7da-599095aa5fdd"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) produces a
                            metabolic alkalinizing effect. Acetate ions are metabolized ultimately
                            to <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and water, which requires the consumption of hydrogen
                            cations.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-1ce683be-7f78-449a-a87f-845a53ef481d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-fd2fa186-887e-46a7-be62-2efcad3c2164"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) is indicated as
                            a source of water and electrolytes or as an alkalinizing
                        agent.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-f8f0560f-5554-43ca-a52d-49d1ec130e8c"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-68ab1233-42d3-4e6d-8836-58e89ad85008"></a>None
                        known</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="INV-3ea38c13-7218-43a1-a746-2f4e9f265dc9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="INV-f701edf1-d450-441b-b38a-bff4545681aa"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) should be used
                            with great care, if at all, in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>,
                            severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in clinical states in which there exists
                            <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> with <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
<p><a name="INV-de86b2a6-a9f4-4eb9-8b57-a3195f6985ed"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) should be used
                            with great care, if at all, in patients with <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, severe renal
                            failure and in conditions in which potassium retention is present.</p>
<p><a name="INV-cebdb455-5954-422d-9836-99f0da809d77"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) should be used
                            with great care in patients with metabolic or <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span>. The
                            administration of acetate ions should be done with great care in those
                            conditions in which there is an increased level or an impaired
                            utilization of these ions, such as severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
<p><a name="INV-ca939985-91e5-4316-8726-a766abd928d9"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) should not be
                            administered simultaneously with blood through the same administration
                            set because of the possibility of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>.</p>
<p><a name="INV-43fc6e92-1bd9-4904-b72f-8046ba8280ce"></a>The intravenous
                            administration of PLASMA-LYTE 56 Injection (Multiple Electrolytes
                            Injection, Type 1, USP) can cause fluid and/or solute overloading
                            resulting in dilution of serum electrolyte concentrations,
                            <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, congested states or <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. The risk of
                            dilutional states is inversely proportional to the electrolyte
                            concentrations of the injection. The risk of solute overload causing
                            congested states with peripheral and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> is directly
                            proportional to the electrolyte concentrations of the injection.</p>
<p><a name="INV-2b2a2395-9c30-4b2e-a98b-d22e8694c694"></a>In patients with
                            diminished renal function, administration of PLASMA-LYTE 56 Injection
                            (Multiple Electrolytes Injection, Type 1, USP) may result in sodium or
                            potassium retention.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="INV-98e7e9d9-3086-4aa5-b4ba-6ea9aa9382fd"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><a name="INV-104c1b17-2dca-4790-8fba-37a8fd1995f7"></a>Clinical evaluation
                            and periodic laboratory determinations are necessary to monitor changes
                            in fluid balance, electrolyte concentrations and acid base balance
                            during prolonged parenteral therapy or whenever the condition of the
                            patient warrants such evaluation.</p>
<p><a name="INV-c8f0b1c9-a5e2-4c6b-8075-7795d877681d"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) should be used
                            with caution. Excess administration may result in <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.</p>
<p><a name="INV-07471179-4991-47a5-89e3-98116c083c0f"></a>Caution must be
                            exercised in the administration of PLASMA-LYTE 56 Injection (Multiple
                            Electrolytes Injection, Type 1, USP) to patients receiving
                            corticosteroids or corticotropin.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="INV-367e93c9-57fd-4b80-bf96-a58d0ed29bbe"></a><a name="section-7.1"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="INV-29d0e455-62b0-4408-9404-c70b4f2ce939"></a><a name="section-7.1.1"></a><p></p>
<h3>Teratogenic
                                        Effects</h3>
<div class="Section">
<a name="section-7.1.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First"><a name="INV-2c6d8602-6f58-44b6-89a1-dca3b3055525"></a>Animal reproduction studies have not been
                                                  conducted with PLASMA-LYTE 56 Injection
                                                  (Multiple Electrolytes Injection, Type 1, USP).
                                                  It is also not known whether PLASMA-LYTE 56
                                                  Injection (Multiple Electrolytes Injection, Type
                                                  1, USP) can cause fetal harm when administered
                                                  to a pregnant woman or can affect reproduction
                                                  capacity. PLASMA-LYTE 56 Injection (Multiple
                                                  Electrolytes Injection, Type 1, USP) should be
                                                  given to a pregnant woman only if clearly
                                                  needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="INV-a1ff6614-9a55-441b-9c56-73c255fa3a4c"></a><a name="section-7.2"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="INV-607d7bed-b526-4076-a1b3-eb1cecdecd5b"></a>Safety and
                                    effectiveness of PLASMA-LYTE 56 Injection (Multiple Electrolytes
                                    Injection, Type 1, USP) in pediatric patients have not been
                                    established by adequate and well controlled trials, however, the
                                    use of electrolyte solutions in the pediatric population is
                                    referenced in the medical literature. The warnings, precautions
                                    and adverse reactions identified in the label copy should be
                                    observed in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="INV-74b466f8-b788-448c-bb94-924e2d713325"></a><a name="section-7.3"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><a name="INV-2428219e-f545-4362-8ef7-bb7e7d5c59b4"></a>Clinical
                                    studies of PLASMA-LYTE 56 Injection (Multiple Electrolytes
                                    Injection, Type 1, USP) did not include sufficient numbers of
                                    subjects aged 65 and over to determine whether they respond
                                    differently from younger subjects. Other reported clinical
                                    experience has not identified differences in responses between
                                    the elderly and younger patients. In general, dose selection for
                                    an elderly patient should be cautious, usually starting at the
                                    low end of the dosing range, reflecting the greater frequency of
                                    decreased hepatic, renal, or cardiac function, and of
                                    concomitant disease or drug therapy.</p>
<p><a name="INV-7b3e3a56-8775-454c-b321-06ba92886565"></a>Do not
                                    administer unless solution is clear and seal is
                                intact.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-95af6ef3-87f8-4172-8688-d9c15903b150"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="INV-6f0e386d-c846-4e08-9f04-9eed7a4692ec"></a>Reactions which may
                            occur because of the solution or the technique of administration include
                            febrile response, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the site of injection, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>                          or <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> extending from the site of injection, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> and
                            <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>.</p>
<p><a name="INV-9c1dcf82-17e4-45f0-acfd-51c5fbff35b2"></a>If an adverse
                            reaction does occur, discontinue the infusion, evaluate the patient,
                            institute appropriate therapeutic countermeasures and save the remainder
                            of the fluid for examination if deemed necessary.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-9a709344-2914-45b2-9706-6fea1c70a743"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="INV-a80cd24f-ddc3-4904-b8a1-6952afd8ff72"></a>As directed by a
                            physician. Dosage is dependent upon the age, weight and clinical
                            condition of the patient as well as laboratory determinations.</p>
<p><a name="INV-e85fdc30-f735-4c7f-b91a-a6d9fc13960e"></a>Parenteral drug
                            products should be inspected visually for particulate matter and
                            discoloration prior to administration whenever solution and container
                            permit.</p>
<p><a name="INV-fc40a51f-6f98-4925-9b5c-b600a7630d16"></a>All injections in
                            VIAFLEX plastic containers are intended for intravenous administration
                            using sterile equipment.</p>
<p><a name="INV-27d0bb3c-ccfe-4d42-a327-b3636bcde755"></a>Additives may be
                            incompatible. Complete information is not available. Those additives
                            known to be incompatible should not be used. Consult with pharmacist, if
                            available. If, in the informed judgment of the physician, it is deemed
                            advisable to introduce additives, use aseptic technique. Mix thoroughly
                            when additives have been introduced. Do not store solutions containing
                            additives.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-8509b622-2a1f-424c-b9ca-b32aef9566a2"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="INV-6242891b-3f09-469e-9e74-b59bb55f9ad5"></a>PLASMA-LYTE 56
                            Injection (Multiple Electrolytes Injection, Type 1, USP) in VIAFLEX
                            plastic containers is available as shown below:</p>
<table frame="void">
<col align="left" width="150pt">
<col align="left" width="150pt">
<col align="left" width="150pt">
<thead valign="bottom"><tr class="Last" valign="bottom">
<td align="center" valign="middle">Code</td>
<td align="center" valign="middle">Size(mL)</td>
<td align="center" valign="middle">NDC</td>
</tr></thead>
<tbody valign="top"><tr class="Last" valign="top">
<td align="center" valign="middle">2B2524</td>
<td align="center" valign="middle">1000</td>
<td align="center" valign="middle">NDC 0338-0168-04</td>
</tr></tbody>
</table>
<p><a name="INV-030a212d-0aef-4667-85ac-301886f8f622"></a>Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. It is recommended the product be stored at room temperature
                            (25°C); brief exposure up to 40°C does not adversely affect the
                        product.</p>
</div>
<div class="Section">
<a name="INV-f8dff056-738d-447a-87dc-8f7c7dfb3cf7"></a><a name="section-11"></a><p></p>
<h1>DIRECTIONS FOR USE OF
                        VIAFLEX PLASTIC CONTAINER</h1>
<p class="First"><a name="INV-3e4f42dd-ebe1-4b8b-9daa-47758927521b"></a><span class="Bold">Warning:</span> Do not use plastic containers in
                            series connections. Such use could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to
                            residual air being drawn from the primary container before
                            administration of the fluid from the secondary container is
                        completed.</p>
<div class="Section">
<a name="INV-d7e9de99-8dc7-4068-81c3-ed3e8d1a0df7"></a><a name="section-11.1"></a><p></p>
<h2>To Open</h2>
<p class="First"><a name="INV-2b01dcc3-d3b9-4066-95f4-caa024b96ee1"></a>Tear
                                    overwrap down side at slit and remove solution container. Some
                                    opacity of the plastic due to moisture absorption during the
                                    sterilization process may be observed. This is normal and does
                                    not affect the solution quality or safety. The opacity will
                                    diminish gradually. Check for minute leaks by squeezing inner
                                    bag firmly. If leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span>
                                    may be impaired. If supplemental medication is desired, follow
                                    directions below.</p>
</div>
<div class="Section">
<a name="INV-5895252b-7019-4b35-b364-d917ab515035"></a><a name="section-11.2"></a><p></p>
<h2>Preparation for Administration</h2>
<ol class="Arabic">
<li>Suspend container from eyelet support.</li>
<li>Remove plastic protector from outlet port at bottom of
                                        container.</li>
<li>Attach administration set. Refer to complete directions
                                        accompanying set.</li>
</ol>
</div>
<div class="Section">
<a name="INV-0af0b5e9-06a4-40df-aab5-ddd5c8c2e72e"></a><a name="section-11.3"></a><p></p>
<h2>To Add Medication</h2>
<p class="First"><a name="INV-fa9be8e7-572c-4d6a-881a-62287683f022"></a><span class="Bold">Warning:</span> Additives may be
                                    incompatible.</p>
<div class="Section">
<a name="INV-a91b4a6e-8748-4ad3-bf25-63152173d878"></a><a name="section-11.3.1"></a><p></p>
<h3>To add
                                        medication before solution administration</h3>
<ol class="Arabic">
<li>Prepare medication site.</li>
<li>Using syringe with 19 to 22 gauge needle, puncture
                                                resealable medication port and inject.</li>
<li>Mix solution and medication thoroughly. For high
                                                density medication such as potassium chloride,
                                                squeeze ports while ports are upright and mix
                                                thoroughly.</li>
</ol>
</div>
<div class="Section">
<a name="INV-661933c4-9bc2-40fe-a770-1ec3e8fe095c"></a><a name="section-11.3.2"></a><p></p>
<h3>To add
                                        medication during solution administration</h3>
<ol class="Arabic">
<li>Close clamp on the set.</li>
<li>Prepare medication site.</li>
<li>Using syringe with 19 to 22 gauge needle, puncture
                                                resealable medication port and inject.</li>
<li>Remove container from IV pole and/or turn to an
                                                upright position.</li>
<li>Evacuate both ports by squeezing them while
                                                container is in the upright position.</li>
<li>Mix solution and medication thoroughly.</li>
<li>Return container to in use position and continue
                                                administration.</li>
</ol>
<p class="First"><a name="INV-490064ab-3abe-4e93-981b-abf0fd620bdf"></a><span class="Bold">Baxter Healthcare
                                            Corporation</span></p>
<p><a name="INV-17ab179e-c5b4-4234-bb87-908e6acb9d79"></a>Deerfield, IL 60015 USA</p>
<p><a name="INV-64f63f43-37d8-400a-a0c5-3e060c330eb6"></a>Printed in USA</p>
<p><a name="INV-14ff9439-19a7-46c8-aa05-bef9aced365f"></a>*Bar Code Position Only</p>
<p><a name="INV-d70f6d15-aa28-4fb4-93d5-a99d21b101fc"></a>071942878</p>
<p><a name="INV-edb1ec37-42d8-45b5-8426-1963501a6461"></a><span class="Bold">07-19-42-878 Rev. February
                                                2004</span></p>
<p><a name="INV-3e74530a-4245-4d35-a0a2-2e8d5b6882c8"></a>Baxter, PLASMA-LYTE, VIAFLEX, and PL 146 are</p>
<p><a name="INV-44572c00-467d-4732-882f-c5b1c0d49c4d"></a>trademarks of Baxter International Inc.</p>
</div>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PLASMA-LYTE 56 		
					</strong><br><span class="contentTableReg">sodium chloride, potassium acetate, magnesium acetate tetrahydrate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0168</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sodium Chloride</strong> (Sodium Chloride) </td>
<td class="formItem"></td>
<td class="formItem">2.34 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Potassium Acetate</strong> (Potassium Acetate) </td>
<td class="formItem"></td>
<td class="formItem">1.28 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Magnesium Acetate Tetrahydrate</strong> (Magnesium Acetate Tetrahydrate) </td>
<td class="formItem"></td>
<td class="formItem">.23 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0168-04</td>
<td class="formItem">1000 mL in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>94c12711-d672-450d-baae-06e24a72aace</div>
<div>Set id: 94c12711-d672-450d-baae-06e24a72aace</div>
<div>Version: 1</div>
<div>Effective Time: 20060919</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
